Zhenping Zhu, MD, PhD

Dr. Zhenping Zhu is currently Executive Vice President, Global Biopharmaceuticals, Kadmon Corporation, New York, and President and CEO of Kadmon China. Prior to joining Kadmon, Dr. Zhu was Vice President and Global Head, Protein Sciences and Design, at Novartis Biologics. At Novartis, Dr. Zhu established and led research groups globally in Basel (Switzerland), Cambridge (US), and Shanghai (China), and was responsible for the discovery, design and selection of novel biologics medicines that address various diseases of high unmet need. Prior to Novartis, Dr. Zhu worked over 12 years at ImClone Systems as Vice President of Antibody Technology and Immunology, and has successfully led research teams that discovered and engineered several novel antibodies that are currently in clinical development for various oncology indications. From 1996 to 2006, Dr. Zhu held an adjunct professorship at the Institute of Hematology, Chinese Academy of Medical Sciences. Dr. Zhu has been working in the biopharmaceutical industry for over 20 years, and has published over 180 peer-reviewed scientific articles, including original research papers, invited reviews and book chapters.

Dr. Zhu earned his medical degree from Jiangxi Medical College (Nanchang, China), passed USMLE and is certified by US ECFMG. He received his MSc in Pharmacology from the Institute of Hematology, Chinese Academy of Medical Sciences and Peking Union Medical College (Beijing, China), and his PhD in Immunology and Pathology from Dalhousie University (Halifax, Canada). Dr. Zhu performed his postdoctoral work in antibody/protein engineering at Genentech Inc.